- The European Commission approved Poulvac® Procerta® HVT-ND for protection against Newcastle disease and Marek’s disease.
- The recombinant vector vaccine can be administered either in ovo or by subcutaneous injection at hatch.
- The approval expands Zoetis’ Procerta vaccine portfolio in Europe, which now includes three EC-authorized products.
- Zoetis says the authorization also supports export opportunities for poultry producers in regions where the vaccine is already approved.
- Recent Newcastle disease outbreaks in several European countries underscore continued demand for preventive vaccination programs.
Zoetis has received European Commission marketing authorization for Poulvac® Procerta® HVT-ND, adding another recombinant vector vaccine to its growing poultry biologics portfolio in the European Union.
The vaccine provides protection against both Newcastle disease (ND) and Marek’s disease through a single administration and may be delivered either in ovo or by subcutaneous injection at hatch. The approval expands Zoetis’ lineup of HVT vector vaccines available to European poultry producers and veterinarians.
Expanding a Strategic Poultry Vaccine Portfolio
Poulvac Procerta HVT-ND becomes the third vaccine in the Procerta portfolio to receive European Commission authorization. The portfolio also includes Poulvac Procerta HVT-IBD, which protects against infectious bursal disease and Marek’s disease, and Poulvac Procerta HVT-IBD-ND, authorized in 2025 for protection against Newcastle disease, infectious bursal disease and Marek’s disease.
The vaccine uses a herpesvirus of turkey (HVT) vector to express a Newcastle disease virus antigen while simultaneously providing protection against Marek’s disease.
For poultry health marketers and commercial teams, the expanded portfolio allows Zoetis to offer producers multiple vaccination options tailored to different disease prevention strategies while reinforcing its position in the competitive global poultry vaccine market.
Market Timing Amid Disease Pressure
The authorization comes as Newcastle disease continues to challenge poultry production across Europe, with recent outbreaks reported in Germany, Spain and Poland. Because Newcastle disease is a notifiable disease under European Union animal health regulations, effective vaccination remains a critical component of flock health programs.
Zoetis also noted that the EU authorization complements approvals already in place in more than 35 other global markets and could facilitate export opportunities for poultry producers in Southeast Asia where the vaccine is already available.
The company said it will work with veterinarians and poultry producers to incorporate the vaccine into flock health programs across Europe.
Information sourced from a Zoetis press release.
